Influenza is a highly infectious acute respiratory disease that is estimated to result globally in 3–5 million cases of severe illness and 290 000–650 000 deaths annually.\textsuperscript{1,2} Children aged <5 years are more susceptible to infection, with an estimated annual attack rate of 20–30%, compared with adults at 5–10%, with the elderly having the highest risk of mortality.\textsuperscript{3}

Syndromic and virological surveillance of influenza-like illness (ILI) and severe acute respiratory infection (SARI) are used to understand and estimate the burden of influenza. The data generated can be used to identify populations at high risk of infection and of complications, provide early warning of potential epidemics and guide preparedness, resource allocation, selection of preventive, treatment and control measures and selection of strains for seasonal flu vaccination.\textsuperscript{4} In developing, low-income countries such as Mongolia, however, the burden of influenza is poorly quantified.\textsuperscript{5,6} In 2015, the World Health Organization (WHO) published A Manual for Estimating Disease Burden Associated with Seasonal Influenza to guide comparable studies of disease burden with a uniform method.\textsuperscript{7} The method is based on available data from national surveillance that countries may use annually and will result in comparable results across time and geography if the surveillance methods are applied consistently.
Mongolia is a landlocked country in east and central Asia. The population of about 3 million people is relatively young with 65% aged <35 years. Children aged <5 years and people aged >65 years constitute 13% and 4% of the population, respectively. The temperature ranges from approximately −30 °C to 40 °C, and the capital, Ulaanbaatar, in which nearly half the population resides, is considered the coldest capital city in the world. One third of the population resides in rural areas, breeding livestock in nomadic and semi-nomadic pastoralism. The country’s harsh climate and nomadic lifestyle make the population vulnerable to acute respiratory infections, particularly influenza.

Several studies of sentinel surveillance of ILI and SARI and a cohort study conducted in a district family general practice 130 km east of Ulaanbaatar in 2010–2011 showed that, between 2007–2008 and 2011–2012, children aged <5 years had the highest incidence, accounted for almost all cases of ILI and SARI and had the highest attack rate of laboratory-confirmed influenza. In this study, we sought to further elucidate the burden of influenza in Mongolia. Syndromic and laboratory surveillance data were used to compare morbidity and mortality, and to estimate the disease burden associated with seasonal influenza with the standardized protocol described in the WHO manual, in Mongolia between 2013–2014 and 2017–2018.

METHODS

Health facilities in Mongolia

Administratively, Mongolia is divided into nine districts in the capital, Ulaanbaatar, and 21 provinces; the provinces are divided into subregions called soums. Outpatients are managed in the capital districts in 218 family health centres and in the provinces and soums in 296 soum health centres. Data on ILI are collected from all outpatient sites in the country and reported weekly to the nine district health departments in the capital and 21 provincial health departments and then forwarded to the National Centre for Communicable Diseases (NCCD). The data collected and reported to the flu information system (www.flu.mn) consisted of the total number of outpatient visits to family group practices, the total number of ILI cases, the number of clusters, the total number of ambulance calls and the total number of calls due to ILI.

The largest hospitals in the country are general hospitals, regional centres for diagnosis and treatment and specialized hospitals known as reference centres. There are general hospitals in each of the capital districts and in 16 provinces and regional centres for diagnosis and treatment in five provinces. Although all public health facilities participate in influenza surveillance, cases diagnosed and treated in private hospitals are not reported. The proportions of patients treated in public and private facilities were not available.

Sentinel surveillance

The WHO case definitions of ILI and SARI were used. An ILI case was defined as an acute respiratory infection with measured fever of >38 °C and cough with onset within the previous 10 days. A SARI case was defined as an acute respiratory infection with a history of fever or measured fever of >38 °C and cough with onset within the previous 10 days and requiring hospitalization.

ILI surveillance with specimen collection has been conducted at 115 sentinel outpatient sites throughout the country (23 in the capital and 92 in the provinces) since 2009. The sites report data on ILI daily. The sampling and testing methods are described under “Specimen collection and testing” below. SARI surveillance has been conducted at 37 hospitals since 2009, of which 16 are provincial general hospitals (located in provincial capital cities), five are regional centres for diagnosis and treatment, nine are district general hospitals in the capital, three are soum hospitals (one in the coldest part of the country, one in the south close to a major border crossing with China and the other in the north close to a major border crossing with the Russian Federation) and four are reference centres (National Centre of Maternal and Child Health, National Cancer Centre, State Hospital Number 3 and the NCCD hospital). The hospitals report data on SARI inpatients once a week. The data collected and reported to the flu information system consisted of the total number of patients at the end of the previous week, the total number of recovered and shifted patients, deaths, total number of newly admitted patients, number of patients at the end of the current week, total number of SARI patients at the end of the previous week, total number of recovered and shifted patients, deaths, total number of newly admitted SARI patients and total number of SARI patients at the end of the current week.
Specimen collection and testing

The sentinel surveillance sites are classified into one of two categories according to the frequency of specimen collection. Category I sites \((n = 78): 61\) outpatient sites and 17 hospitals) collect and send specimens for testing every week, and category II sites \((n = 74): 54\) outpatient sites and 20 hospitals) collect and send specimens for testing only during the influenza season or if an outbreak or cluster is detected at the site.

Physicians at ILI and SARI sentinel sites were asked to collect nasopharyngeal swabs each week from 5–10 patients who met the case definitions within 3 days of disease onset and before treatment. The collected specimens were immediately immersed into sterile tubes containing virus transport medium, stored in refrigerators at the sentinel sites and transported to the Reference Virology Laboratory of the National Influenza Centre at the NCCD or to one of four participating branch laboratories. Samples were shipped by car from the central region, by plane from the western and eastern regions and by train from the northern and south-eastern regions. Samples were tested for influenza virus by real-time reverse transcriptase polymerase chain reaction. Virus-positive samples were passaged in MDCK cells for isolation. Genetic sequencing analysis was done for five strains of A(H1N1)pdm09 and eight strains of A(H3N2) by ABI Big Dye terminator v.3.1 Cycle Sequencing and ABI 3130 xl Analyser.

Analysis of epidemiological data and burden of disease

Data from the ILI, SARI and laboratory surveillance systems in the 2013–2014 and 2017–2018 influenza seasons were analysed to elucidate the epidemiology of influenza in Mongolia. As the annual influenza season crosses the new calendar year, seasons were defined as from week 40 of one year to week 39 of the following year. ILI incidence rates were calculated from population data for the whole country and total consultations and for the populations of the capital city districts and provincial capital cities. SARI incidence rates were calculated from total hospitalizations and the populations of the provincial capitals and the districts of the national capital, representing the catchment populations of the SARI sentinel sites. An influenza season was defined as the period between the date on which the ILI rate crossed the median weekly ILI threshold rate for 2013–2014 to 2017–2018. Laboratory data were analysed by influenza type or subtype and the percentage of specimens tested that were positive for influenza.

These data were used to estimate overall and age-specific (age groups: <2, 2–<5, 5–<15, 15–<50, 50–<65, and ≥65 years) influenza-associated medically attended ILI and SARI incidence rates for each season between 2013–2014 and 2017–2018, as described in WHO’s A Manual for Estimating Disease Burden Associated with Seasonal Influenza.

Population mortality and case fatality rates were estimated from the ILI and SARI surveillance data collected throughout the season. Influenza-associated mortality and case fatality rates were not estimated, as samples were not taken from all people who died from SARI. Microsoft Excel® 2013 software was used for the data analyses.

RESULTS

Between 2013–2014 and 2017–2018, 2 002 825 patients with ILI and 205 991 with SARI were reported per year (ranges, 371 491–440 389 for ILI and 33 136–50 759 for SARI). The seasonal peak rates were 50–70 ILI cases and 6–10 SARI cases per 10 000 population (Fig. 1). The peak rates were highest for both ILI and SARI in the 2016–2017 season, while the lowest peaks were in 2014–2015 and 2013–2014, respectively.

During the five seasons, the number of SARI patients increased, as both a proportion of hospital admissions and incidence rate, while the number of ILI patients decreased as a proportion of consultations and incidence rate (Table 1). The 5-year averages were 532.4 ILI cases and 42 SARI cases per 100 000 population.

Seasons started between weeks 40 and 44, but the timing of the peaks (weeks 51 to 9) and the ends (weeks 7 to 22) varied more widely (Table 1, Fig. 1 and 2). The longest season was that of 2013–2014 (35 weeks), and the shortest was that of 2016–2017 (16 weeks).

Influenza virus was detected in the population in each of the five seasons of 2013–2014 to 2017–2018.
Influenza epidemiology and burden of disease in Mongolia, 2013–2014 to 2017–2018

Darmaa et al

Fig. 1. ILI and SARI rates per 10 000 population by week, Mongolia, 2013–2014 to 2017–2018

Table 1. ILI consultations and SARI hospitalizations, incidence rates and season characteristics by year, Mongolia, 2013–2014 to 2017–2018

| Influenza season | 2013–2014 | 2014–2015 | 2015–2016 | 2016–2017 | 2017–2018 | 5-year average |
|------------------|-----------|-----------|-----------|-----------|-----------|---------------|
| ILI cases per total outpatient consultations (%) | 5.7 | 5.2 | 4.7 | 4.5 | 4.4 | 4.9 |
| No. of ILI cases per 100,000 population | 15 029 | 13 732 | 13 102 | 12 145 | 11 690 | 13 106 |
| SARI patients among total hospitalizations (%) | 8.4 | 9.2 | 10.3 | 11.1 | 11.8 | 10.2 |
| No. of SARI cases per 100,000 population | 1660 | 1780 | 2079 | 2029 | 2364 | 1990 |
| Season onset (week) | 40 | 41 | 42 | 44 | 43 | |
| Season peak (week) | 8 | 51 | 9 | 1 | 52 | |
| Season end (week) | 22 | 13 | 19 | 7 | 16 | |
Two seasons (2013–2014 and 2014–2015) started earlier, with most cases detected in weeks 2–17, peaking in weeks 3–11 (Fig. 3). Most cases in seasons 2015–2016, 2016–2017 and 2017–2018 were detected in weeks 47–51, with peaks in weeks 51–52. Trends in influenza positivity were similar for ILI and SARI patients. The 2014–2015 and 2016–2017 seasons were dominated by type A/H3N2, while type B co-circulated with type A(H1N1) in 2014–2015 and 2017–2018, with two distinct peaks in each season. All three types or subtypes co-circulated in 2013–2014. The percentage of tests positive for influenza virus was highest for both ILI and SARI patients in 2016–2017; however, over each full year, there was more variation in the percentage of ILI patients positive for influenza (range: 9–19%; lowest in 2014–2015 and highest in 2013–2014) than of SARI patients (range: 8–12%; lowest in 2014–2015 and highest in 2017–2018).

The highest proportions of the population positive for both ILI and SARI from 2013–2017 to 2017–2018 were reported in children aged <5 years (Tables 2 and 3). In seasons 2015–2016, 2016–2017 and 2017–2018, for which fewer data were available by age group, the proportions were highest among those aged <2 years. The proportions of age group-specific ILI generally decreased with age, whereas for SARI, the proportions decreased with age to 50 years and then increased for older age groups.

The estimated annual influenza-associated ILI and SARI rates, presented as ranges, were 1279–2798 and 81–666 cases per 100 000 population, respectively. (Tables 2 and 3) The rates were highest for children aged <5 years (especially those aged <2 years) and lowest for people aged 15–<50 years. There was wider variation between the minimum and maximum annual rates of SARI (42%) than for ILI (29%). The annual rates of ILI decreased each year during the study period, while the rates of SARI increased.

The annual mortality rate due to SARI ranged from 1.2 to 3.9 deaths per 100 000 population between 2013–2014 and 2017–2018. The rate was highest among children aged <5 years, in particular those aged <2 years (15.8–54.0 deaths per 100 000 population in 2015–2016 to 2017–2018). Annual mortality rates were <1.0 deaths among people aged 5–50 years, increasing to 1.2–5.1 deaths per 100 000 population for those aged ≥65 years (Table 4).
Fig. 3. Numbers of ILI cases (3A) and SARI cases (3B) positive for influenza by type or subtype and percentages influenza positive, Mongolia, 2013–2014 to 2017–2018
Table 2. **Range of annual ILI cases, incidence and per cent influenza positive by age group, 2013–2014 to 2017–2018**

| Age group (years) | Total outpatient consultations | ILI cases | ILI cases per 100 000 population | % specimens influenza positive | Estimated % total consultations for influenza-associated ILI | Estimated influenza-associated ILI per 100 000 population |
|------------------|-------------------------------|-----------|---------------------------------|-----------------------------|--------------------------------------------------------|----------------------------------------------------------|
| Total            | 1 228 239–1 354 384          | 148 950–174 258 | 96 575–108 028 | 488–638 | 3–1.6 | 10 498–13 476 |
| <2*              | 765 072–804 931             | 100 979–104 964 | 42 118–46 535 | 495–651 | 0.8–1.9 | 578–8435 |
| 2–<5*            | 1 955 342–2 180 652         | 249 929–285 412 | 63 436–87 486 | 667–1289 | 0.9–2.8 | 4958–10 079 |
| <5               | 877 738–1 086 993           | 71 670–101 315 | 13 097–20 981 | 295–736 | 0.1–0.3 | 1642–6313 |
| 5–<15            | 2 632 829–3 666 852         | 34 472–41 364 | 2007–2411 | 230–417 | 0.0–0.1 | 191–457 |
| ≥50              | 1 714 888–2 135 206         | 9867–18 261 | 1852–2108 | 76–380 | 0.1–0.1 | 203–618 |
| 50–<65*          | 1 117 744–1 322 442         | 6170–7792 | 3239–3368 | 55–68 | 0.0–0.1 | 168–500 |
| ≥65*             | 721 168–812 764             | 3727–4133 | 7371–440 389 | 17–32 | 11 690–15 029 |

* For seasons 2015–2016, 2016–2017 and 2017–2018 only

Table 3. **Range of annual SARI cases, incidence and per cent influenza positive by age group, 2013–2014 to 2017–2018**

| Age group (years) | Total admissions | SARI cases | SARI cases per 100 000 population | % specimens influenza positive | Estimated % total hospitalizations for influenza-associated SARI | Estimated influenza-associated SARI per 100 000 population |
|------------------|-----------------|------------|----------------------------------|-----------------------------|---------------------------------------------------------------|-----------------------------------------------------------|
| Total            | 54 095–66 759   | 25 018–27 392 | 23 315–26 197 | 756–804 | 8–31 | 1798–8039 |
| <2*              | 20 389–28 077   | 9724–12 640 | 6359–7777 | 434–563 | 11–30 | 697–2311 |
| 2–<5*            | 72 470–87 148   | 26 476–40 032 | 12 226–14 988 | 1190–1725 | 0.8–1.9 | 530–4547 |
| <5               | 20 209–24 850   | 3003–6103 | 894–1569 | 124–209 | 0.9–2.8 | 103–316 |
| 5–<15            | 154 586–204 850 | 1391–2 654 | 956–1906 | 66–337 | 0.0–0.1 | 8–23 |
| ≥50              | 105 027–122 039 | 1043–1961 | 344–588 | 17–119 | 0.0–0.1 | 14–104 |
| 50–<65*          | 62 124–69 403   | 758–1034 | 336–413 | 13–51 | 0.1–0.2 | 32–57 |
| ≥65*             | 41 738–52 636   | 621–927 | 781–1114 | 4–25 | 0.5–0.9 | 65–557 |

* For seasons 2015–2016, 2016–2017 and 2017–2018 only
DISCUSSION

In this first study of the influenza burden in Mongolia, estimated with WHO’s A Manual for Estimating Disease Burden Associated with Seasonal Influenza, the burden of influenza-associated ILI and SARI was highest among children aged <5 years, especially among those aged <2 years, consistent with a study conducted with the same methods on the epidemiology and impact of influenza in Mongolia between 2007 and 2012. The estimated annual influenza-associated ILI and SARI rates, presented as ranges, were 1279–2798 and 81–666 cases per 100 000 population, respectively; the rates in children aged <5 years were 4958–10 079 and 530–4547 per 100 000 population, respectively. These rates are higher than those in other published studies of influenza in low- and middle-income countries (LMICs), as classified by The World Bank. For example, the influenza-associated SARI rates per 100 000 population for all ages and for children aged <5 years, respectively, were: 115–142 and 2021–2349 in China; 13–19 and 82–114 in Indonesia; 21–82 and 147–469 (in children aged <2 years) in Kenya; and 43.9 and 187.7 in Zambia. The studies should be compared cautiously, as the same (WHO) SARI case definition was used only in Indonesia and Kenya, and the rates were from a relatively small number of hospitals and extrapolated to provincial or national levels.

The outcomes of influenza may be more severe in LMICs than in high-income countries, particularly in pregnant women, people living with HIV/AIDS and children aged <5 years, contributing to a disproportionate proportion of the global burden of influenza. There are several possible explanations for the very high rates observed in Mongolia. The extreme winter results in increased occupation of indoor spaces and may reduce immunity in some population groups. Increased population mixing also occurs in winter during public holidays, particularly the Lunar New Year and the beginning of the school year. Smoke and pollution caused by burning coal may exacerbate respiratory conditions and increase vulnerability to influenza infection.

The wide range of annual estimates of influenza-associated SARI in particular is partly driven by the marked, consistent increase in annual SARI rates over the 5-year study period. The reason for this increase has not been established, but hospitals may have changed the diagnostic and admission criteria for SARI to maximize government assistance payments for admitted SARI cases.

Only limited quantities of influenza vaccine are available in Mongolia, provided by the Government and the Partnership for Influenza Vaccine Introduction programme (https://pivipartners.org/). The Government subsidized influenza vaccination for health-care workers and staff in emergency agencies following the influenza A(H1N1)pdm09 pandemic in 2009, but vaccination remains voluntary and requires payment by other groups, so that very few people are vaccinated each year. The high influenza-associated ILI and SARI burden and mortality from pneumonia and SARI in children indicate that a vaccination programme for children could have an enormous impact on the burden of influenza in Mongolia. It would require considerable funding and resources in view of the high proportion of youth in the population. This population structure is common in developing countries, where 99% of deaths attributable to influenza-associated acute lower respiratory infection deaths in children aged <5 years occur.

In the five influenza seasons between 2013–2014 and 2017–2018, ILI and SARI activity in Mongolia usually started in October and peaked during the coldest period of the year between late December and February. As measured by the percentage of samples from ILI and SARI patients who tested positive for influenza, the highest seasonal load was in 2016–2017 and the lowest in 2014–2015. In the 2015–2016 and 2017–2018 seasons, distinct secondary peaks were seen, associated with other influenza types and subtypes that dominated later in the seasons. The subtype distribution was consistent in the ILI and SARI surveillance systems each year, influenza A(H3) being the predominant circulating subtype in 2014–2015.

The timing and distributions of type and subtype in each of the five influenza seasons varied during the surveillance period and were not always consistent with observations from other regions of the northern hemisphere. Between 2013–2014 and 2016–2017, the subtype distribution in Mongolia was similar to those of North America and of north and east Asia (particularly China, Japan and the Republic of Korea) in each of the four seasons and to that of Europe in three seasons; however, the timing of the seasons was similar to those
of these regions in only two of the four seasons. In 2017–2018, the timing and subtype distribution best matched that observed in western Europe. The difference between the seasonal pattern in Mongolia and those in other countries in north and east Asia and elsewhere in the northern hemisphere highlights the importance of national surveillance in understanding influenza epidemiology and virology in Mongolia.

Our study had several limitations. A high staff workload, limited availability of swab kits, the absence of systematic sampling and the logistical challenges of transporting samples over long distances may have resulted in non-random sampling of ILI and SARI patients. The influenza-associated SARI mortality rate could not be estimated, as not all deaths were confirmed in the laboratory according to surveillance procedures. The positivity rate for influenza virus might have been underestimated due to delayed health care-seeking because of insufficient health literacy and improper use of antibiotics, lengthening the time to presentation to a doctor. Furthermore, reluctance among the elderly to seek health care may have resulted in underestimates of influenza-associated ILI, SARI and mortality rates for this age group. In contrast, SARI rates in the provinces might have been overestimated, as serious cases in soum hospitals are sometimes referred to provincial general hospitals. Lack of more detailed epidemiological and clinical data on cases prevented in-depth analysis of risk factors, such as underlying conditions and geographical distribution.

The estimated incidence of influenza-associated ILI and SARI in Mongolia over five seasons between 2013–2014 and 2017–2018 was higher than that in comparable countries; however, our finding that children under 5 years were the most affected is consistent with regional and global trends. The findings can inform influenza control policies. Targeted vaccination of children would dramatically decrease the burden of influenza in Mongolia. Further improvements to the surveillance system would allow more detailed analysis of risk factors and underlying conditions associated with the severity and economic burden of influenza.

Acknowledgements

The study team acknowledges the WHO Country Office for its financial support. The WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. Technical advice and support were provided by Dr Stella Van Beers of the Royal Tropical Institute, Amsterdam, Netherlands; Sarah Hamid and Dr Erica Dueger, WHO Regional Office for the Western Pacific; and Dr Evlegsuren and Dr Ariuntuya of the WHO Country Office in Mongolia.

References

1. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–300. doi:10.1016/S0140-6736(17)33293-2 pmid:29248255
2. Paget J, Spreeuwenberg P, Charu V, Taylor RJ, Iuliano AD, Bresee J, et al. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J Glob Health. 2019;9(2):020421. doi:10.7189/jogh.09.020421 pmid:31673337
3. Influenza. Geneva: World Health Organization; 2019. Available from: https://www.who.int/biologicals/vaccines/influenza/en/, accessed 10 May 2018.
4. Global epidemiological surveillance standards for influenza. Geneva: World Health Organization; 2013. Available from: https://www.who.int/influenza/resources/documents/influenza_surveillance_manual/en/? accessed 1 December 2013
5. Simmerman JM, Uyeki TM. The burden of influenza in east and South-East Asia: a review of the English language literature. Influenza Other Respir Viruses. 2008;2(3):81–92. doi:10.1111/j.1750-2659.2008.00045.x pmid:19453467

Table 4. Range of annual deaths and rates of mortality due to pneumonia and SARI, 2013–2014 to 2017–2018

| Age group (years) | Deaths due to SARI | Mortality rate per 100 000 population |
|------------------|-------------------|---------------------------------------|
|                  | <2*               | 2–<5*                                 |
|                  | 5–<15             | ≥50                                   |
| <5               | 1–2               | 1–8                                   |
| 5–<15            | 0–5               | 1–4                                   |
| ≥50              | 1–4               | 25–80                                 |

* For seasons 2015–2016, 2016–2017 and 2017–2018 only
6. Lee VJ, Ho ZJM, Goh EH, Campbell H, Cohen C, Cozza V, et al. Advances in measuring influenza burden of disease. Influenza Other Respir Viruses. 2018;12(1):3–9. doi:10.1111/irv.12533 pmid:29460425

7. A manual for estimating disease burden associated with seasonal influenza. Geneva: World Health Organization, WHO Global Influenza Programme; 2015. Available from: https://www.who.int/influenza/resources/publications/manual_burden_of_disease/en/, accessed 10 May 2015.

8. National Statistics Office of Mongolia. Ulaanbaatar; 2021. Available from: http://www.en.nso.mn/index.php, accessed 10 May 2019.

9. The coldest capital cities in the world. World Atlas. Available from: https://www.worldatlas.com/articles/the-coldest-capital-cities-in-the-world.html, accessed 10 May 2017.

10. Lee VJ, Ho ZJM, Goh EH, Campbell H, Cohen C, Cozza V, et al. Advances in measuring influenza burden of disease. Influenza Other Respir Viruses. 2018;12(1):3–9. doi:10.1111/irv.12533 pmid:29460425

11. Nukiwa N, Burmaa A, Kamigaki T, Darmaa B, Od J, Od I, et al. Evaluating influenza disease burden during the 2008–2009 and 2009–2010 influenza seasons in Mongolia. West Pac Surveill Response. 2011;2(1):16–22. doi:10.5365/WPSAR.2010.1.1.004 pmid:23908879

12. Nukiwa-Souma N, Burmaa A, Kamigaki T, Od I, Bayasgalan N, Darmaa B, et al. Influenza transmission in a community during a seasonal influenza A(H3N2) outbreak (2010–2011) in Mongolia: a community-based prospective cohort study. PLoS One. 2012;7(3):e33046.

13. Burmaa A, Kamigaki T, Darmaa B, Nymadawa P, Oshitani H. Epidemiology and impact of influenza in Mongolia, 2007–2012. Influenza Other Respir Viruses. 2014;8(5):530–7. doi:10.1111/irv.12268 pmid:25043147

14. World Bank country and lending groups. Washington, DC: The World Bank; 2019. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups, accessed 10 May 2019.

15. Yu H, Huang J, Huai Y, Guan X, Klena J, Liu S, et al. The substantial hospitalization burden of influenza in central China: surveillance for severe, acute respiratory infection, and influenza viruses, 2010-2012. Influenza Other Respir Viruses. 2014;8(1):53–65. doi:10.1111/irv.12205 pmid:24209711

16. Susilurini NK, Haryanto E, Praptiningsih CY, Mangiri A, Kipuw N, Tarya I, et al. Estimated incidence of influenza-associated severe acute respiratory infections in Indonesia, 2013–2016. Influenza Other Respir Viruses. 2018;12(1):81–7. doi:10.1111/irv.12496 pmid:29205865

17. Dawa JA, Chaves SS, Nyawanda B, Njuguna HN, Makokha C, Otieno NA, et al. National burden of hospitalized and non-hospitalized influenza-associated severe acute respiratory illness in Kenya, 2012–2014. Influenza Other Respir Viruses. 2018;12(1):30–7. doi:10.1111/irv.12488 pmid:29243402

18. Theo A, Tempi A, Cohen AL, Simusika P, Chentulo E, Chikamukwa CM, et al. The national burden of influenza-associated severe acute respiratory illness hospitalization in Zambia, 2011–2014. Influenza Other Respir Viruses. 2018;12(1):46–53. doi:10.1111/irv.12492 pmid:29243406

19. Coleman BL, Fadel SA, Fitzpatrick T, Thomas SM. Risk factors for serious outcomes associated with influenza illness in high-versus low- and middle-income countries: Systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2018;12(1):22–9. doi:10.1111/irv.12504 pmid:29197154

20. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807):1917–30. doi:10.1016/S0140-6736(11)61051-9 pmid: 22078723

21. Review of the 2013–2014 winter influenza season, northern hemisphere. Wkly Epidemiol Rec. 2014;89(23):245–56. pmid:24955460

22. Review of the 2014–2015 influenza season in the northern hemisphere. Wkly Epidemiol Rec. 2015;90(23):281–96. pmid:26050269

23. Review of global influenza activity, October 2015–October 2016. Wkly Epidemiol Rec. 2016;91(51–52):604–22. pmid:27995783

24. Review of global influenza activity, October 2016–October 2017. Wkly Epidemiol Rec. 2017;92(50):761–79. pmid:29250946

25. Review of the 2017–2018 influenza season in the northern hemisphere. Wkly Epidemiol Rec. 2018;93:429–44. Available from: https://apps.who.int/iris/bitstream/handle/10665/274263/ WER9334.pdf